Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary

Basit Öğe Kaydı
dc.authorwosidSaip, pınar/AAT-1500-2020
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.contributor.authorUygun, K
dc.contributor.authorAydiner, A
dc.contributor.authorSaip, P
dc.contributor.authorKocak, Z
dc.contributor.authorBasaran, M
dc.contributor.authorDincer, M
dc.contributor.authorTopuz, E
dc.date.accessioned2024-06-12T11:11:52Z
dc.date.available2024-06-12T11:11:52Z
dc.date.issued2003
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives. The objectives of this study were to evaluate the patients' characteristics and treatment results for 11 recurrent granulosa cell tumors (GCT) of the ovary. Methods. Tumor registries were screened retrospectively for all patients treated between 1979 and 1999 for ovarian tumors at the University of Istanbul. All information about these patients was obtained from operation, pathology, and follow-up reports. Then the clinical data were extracted. The patients were classified in stages according to FIGO criteria. There were 952 ovarian carcinomas, of which 45 were GCT. Eleven of 45 patients (24%) developed recurrent disease on follow-up. Results. All patients but one had advanced (III-IV) disease at diagnosis. The median progression-free interval (PFI) was 16 months (range, 5-39 months) with a marked difference in PFI between patients receiving (24 months) and not receiving (8 months) initial chemotherapy. Among patients received chemotherapy (six patients), two complete and two partial responses were observed, for an overall response rate of 67%. The median survival for all patients was 26 (4-73) months with a longer survival (38 versus 8 months) for patients retreated with a platinum-containing regimen. Conclusions. Despite the fact that small number of treated cases does not allow an adequate evaluation, retreatment with cis-platinum-containing regimens may be the treatment of choice for patients with recurrent disease. (C) 2003 Elsevier Science (USA). All rights reserved.en_US
dc.identifier.doi10.1016/S0090-8258(02)00141-5
dc.identifier.endpage403en_US
dc.identifier.issn0090-8258
dc.identifier.issue3en_US
dc.identifier.pmid12648593en_US
dc.identifier.scopus2-s2.0-0037343164en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage400en_US
dc.identifier.urihttps://doi.org/10.1016/S0090-8258(02)00141-5
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22963
dc.identifier.volume88en_US
dc.identifier.wosWOS:000181726100022en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Inc Elsevier Scienceen_US
dc.relation.ispartofGynecologic Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOvaryen_US
dc.subjectGranulosa Cell Tumorsen_US
dc.subjectRecurrenten_US
dc.subjectChemotherapyen_US
dc.subjectCord-Stromal Tumorsen_US
dc.subjectCombination Chemotherapyen_US
dc.subjectCis-Platinumen_US
dc.subjectCisplatinen_US
dc.subjectBleomycinen_US
dc.subjectCyclophosphamideen_US
dc.subjectDoxorubicinen_US
dc.subjectPrognosisen_US
dc.subjectEtoposideen_US
dc.titleClinical parameters and treatment results in recurrent granulosa cell tumor of the ovaryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu